Jesse A. Coker

This study challenges the role of MCL1 in chemoresistance by showing no evidence of nuclear accumulation or DNA repair interactions in live cancer cells.

This study shows that platelet PAR4 signaling, interacting with estrogen receptor beta, drives glioblastoma progression and immune suppression, with sex-specific effects on survival and TME dynamics.

This study determines the structures of human methionine synthase in apo and cobalamin-bound states, revealing conformational changes and interactions with MMADHC and MTRR that aid in cobalamin loading and activation.

This study develops triazole-based WDR5 inhibitors that show improved brain penetration and antiproliferative activity against glioblastoma CSCs, with synergistic effects when combined with ATAD2 inhibitors.

This study identifies METTL16 as a driver of taxane resistance in TNBC by enhancing ABCB1 translation via m6A modification, showing its therapeutic potential.

The paper identifies false positive inhibitors of NSP14 ExoN due to contaminating divalent cations, highlighting challenges in fragment-based drug development for this target.

This study determines the cryo-EM structure of SLC1A1 bound to an inhibitor, identifies its binding mechanism, and develops improved inhibitors with enhanced cytotoxicity in kidney cancer cells.

This study identifies SLC1A1/EAAT3 as an oncogenic transporter in ccRCC driven by H3K27ac, showing its role in sustaining metabolic programs and its potential as a therapeutic target.